탭메뉴
- 급만성 간질환, 지방간, 간경변증, 간암, 위/대장내시경
주요약력
서울대학교 의과대학 의학과 졸업 (2008)
서울대학교 의과대학 대학원 내과학 석사 (소화기내과, 2014)
서울대학교 의과대학 대학원 내과학 박사 (소화기내과, 2017)
서울대학교병원 인턴 (2008~2009)
서울대학교병원 내과 레지던트 (2009~2013)
서울대학교병원 소화기내과 임상강사 (2013~2015)
서울대학교병원 소화기내과 연구전임의 (2015~2016)
現 강남차병원 소화기내과 조교수 (2016~ )
내과 전문의 (2013)
소화기내시경 전문의 (2014)
소화기내과 분과전문의 (2015)
대한간학회 평생회원
대한간암학회 평생회원
대한내과학회 평생회원
대한소화기내시경학회 평생회원
유럽간학회(EASL) 회원
대한간학회 연구기획위원 (2017~2019)
대한간암학회 연구 간사 (2018~2019)
수상경력 및 논문
2012 대한간학회(KASL) Best Presentation Award, Free Paper
2013 유럽간학회(EASL) Young Investigator Award
2014 대한간학회(KASL) Best Presentation Award, Free Paper
2015 국제간암협회(ILCA) Junior Investigator Award
2016 아시아태평양간학회(APASL) Presidential Award
2016 대한간학회(KASL) Best Presentation Award, Poster Oral
2016 대한간학회(KASL) 간산학술상
1. Cho Y, Lee DH, Oh HS, Seo JY, Lee DH, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jung HC, Yoon YB, Song IS. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Dig Dis Sci. 2012 Oct;57(10):2687-92
2. Cho Y, Lee DH, Chung KH, Jin E, Lee JH, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon JH, Lee HS, Kim CY, Kim YJ. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci. 2013 May;58(5):1363-70.
3. Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH, Lee HS, Kim YJ. Prior exposure to lamivudine increases entecavir-resistance risk in chronic hepatitis B patients without detectable lamivudine-resistance. Antimicrob Agents Chemother. 2014 Mar;58(3):1730-7
4. Cho Y, Park SY, Lee JH, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yoon JW, Kwon JH, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. J Clin Gastroenterol. 2014 May-Jun;48(5):444-9.
5. Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography computed tomography have role in initial staging of hepatocellular carcinoma? PLoS One. 2014 Aug ;9(8):e105679.
6. Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. J Med Virol. 2015 Jun;87(6):999-1007.
7. Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B. 2015;5(6):544–553
8. Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Sofosbuvir-based therapy for the patients with chronic hepatitis C: Early experience in Korea providing its efficacy and safety. Clin Mol Hepatol. 2015 Dec;21(4):358-64.
9. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, L Teperman, J Park, Kim YJ, Suh KS, Yoon JH. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016 May;263(5):842-50.
10. Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH. High titers of anti-HBs prevent rituximab related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol. 2016 Jun;88(6):1010-7.
11. Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH. Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS One. 2016 Aug 5;11(8):e0160822.
12. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Hypoxia enhances tumor-stroma crosstalk that drives the progression of hepatocellular carcinoma. Dig Dis Sci. 2016 Sep;61(9):2568-77.
13. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2016 Oct;83:607-616.
14. Cho Y, Sinn DH, Yu SJ, Gwak GY, Kim JH, Yoo YJ, Jeon DW, Kim TY, Lee HY, Cho EJ, Lee JH, Kim YJ, and Yoon JH. Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B. PLoS One. 2016 Nov 15;11(11):e0165722.
15. Cho Y, Lee J-H, Lee DH, Cho EJ, Yu SJ, Yi N-J, Lee K-W, Kim YJ, Yoon J-H, Suh K-S. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget. 2017 Jul 18;8(29):47555-47564.
서울대학교 의과대학 의학과 졸업 (2008)
서울대학교 의과대학 대학원 내과학 석사 (소화기내과, 2014)
서울대학교 의과대학 대학원 내과학 박사 (소화기내과, 2017)
서울대학교병원 인턴 (2008~2009)
서울대학교병원 내과 레지던트 (2009~2013)
서울대학교병원 소화기내과 임상강사 (2013~2015)
서울대학교병원 소화기내과 연구전임의 (2015~2016)
現 강남차병원 소화기내과 조교수 (2016~ )
내과 전문의 (2013)
소화기내시경 전문의 (2014)
소화기내과 분과전문의 (2015)
대한간학회 평생회원
대한간암학회 평생회원
대한내과학회 평생회원
대한소화기내시경학회 평생회원
유럽간학회(EASL) 회원
대한간학회 연구기획위원 (2017~2019)
대한간암학회 연구 간사 (2018~2019)
수상경력 및 논문
2012 대한간학회(KASL) Best Presentation Award, Free Paper
2013 유럽간학회(EASL) Young Investigator Award
2014 대한간학회(KASL) Best Presentation Award, Free Paper
2015 국제간암협회(ILCA) Junior Investigator Award
2016 아시아태평양간학회(APASL) Presidential Award
2016 대한간학회(KASL) Best Presentation Award, Poster Oral
2016 대한간학회(KASL) 간산학술상
1. Cho Y, Lee DH, Oh HS, Seo JY, Lee DH, Kim N, Jeong SH, Kim JW, Hwang JH, Park YS, Lee SH, Shin CM, Jo HJ, Jung HC, Yoon YB, Song IS. Higher prevalence of obesity in gastric cardia adenocarcinoma compared to gastric non-cardia adenocarcinoma. Dig Dis Sci. 2012 Oct;57(10):2687-92
2. Cho Y, Lee DH, Chung KH, Jin E, Lee JH, Cho EJ, Yu SJ, Kim JW, Jeong SH, Yoon JH, Lee HS, Kim CY, Kim YJ. The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir. Dig Dis Sci. 2013 May;58(5):1363-70.
3. Lee JH, Cho Y, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yu SJ, Yoon JH, Lee HS, Kim YJ. Prior exposure to lamivudine increases entecavir-resistance risk in chronic hepatitis B patients without detectable lamivudine-resistance. Antimicrob Agents Chemother. 2014 Mar;58(3):1730-7
4. Cho Y, Park SY, Lee JH, Lee DH, Lee M, Yoo JJ, Choi WM, Cho YY, Lee YB, Yoon JW, Kwon JH, Cho EJ, Yu SJ, Kim YJ, Yoon JH, Kim CY, Lee HS. High-sensitivity C-reactive Protein Level is an Independent Predictor of Poor Prognosis in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. J Clin Gastroenterol. 2014 May-Jun;48(5):444-9.
5. Cho Y, Lee DH, Lee YB, Lee M, Yoo JJ, Choi WM, Cho YY, Paeng JC, Kang KW, Chung JK, Yu SJ, Lee JH, Yoon JH, Lee HS, Kim YJ. Does 18F-FDG positron emission tomography computed tomography have role in initial staging of hepatocellular carcinoma? PLoS One. 2014 Aug ;9(8):e105679.
6. Cho Y, Lee JH, Yu SJ, Yoon JH, Lee HS, Kim YJ. Comparison of the efficacies of entecavir 0.5 and 1.0 mg combined with adefovir in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analogue treatments. J Med Virol. 2015 Jun;87(6):999-1007.
7. Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B. 2015;5(6):544–553
8. Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ. Sofosbuvir-based therapy for the patients with chronic hepatitis C: Early experience in Korea providing its efficacy and safety. Clin Mol Hepatol. 2015 Dec;21(4):358-64.
9. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, Yu SJ, Lee JW, Yi NJ, Lee KW, Kim SH, Kim JM, Joh JW, L Teperman, J Park, Kim YJ, Suh KS, Yoon JH. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg. 2016 May;263(5):842-50.
10. Cho Y, Yu SJ, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH. High titers of anti-HBs prevent rituximab related viral reactivation in resolved hepatitis B patient with non-Hodgkin’s lymphoma. J Med Virol. 2016 Jun;88(6):1010-7.
11. Cho Y, Lee YB, Lee JH, Lee DH, Cho EJ, Yu SJ, Kim YJ, Kim JI, Im JH, Lee JH, Oh EJ, Yoon JH. Modified AS1411 aptamer suppresses hepatocellular carcinoma by up-regulating galectin-14. PLoS One. 2016 Aug 5;11(8):e0160822.
12. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Hypoxia enhances tumor-stroma crosstalk that drives the progression of hepatocellular carcinoma. Dig Dis Sci. 2016 Sep;61(9):2568-77.
13. Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells. Biomed Pharmacother. 2016 Oct;83:607-616.
14. Cho Y, Sinn DH, Yu SJ, Gwak GY, Kim JH, Yoo YJ, Jeon DW, Kim TY, Lee HY, Cho EJ, Lee JH, Kim YJ, and Yoon JH. Survival analysis of single large (>5 cm) hepatocellular carcinoma patients: BCLC A versus B. PLoS One. 2016 Nov 15;11(11):e0165722.
15. Cho Y, Lee J-H, Lee DH, Cho EJ, Yu SJ, Yi N-J, Lee K-W, Kim YJ, Yoon J-H, Suh K-S. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria. Oncotarget. 2017 Jul 18;8(29):47555-47564.
Copyright ⓒ chamc, All rights reserved.
